Health
A Call for Nuance in Cardioprotection With Early Breast Cancer Therapy – MedPage Today
Longer-term PRADA trial results weigh in for low-risk group
For low-risk breast cancer patients getting potentially cardiotoxic treatment, candesartan’s (Atacand) short-term protection of cardiac function faded longer term in the PRADA trial.
Left ventricular ejection fraction (LVEF) declined a similar amount from baseline to 23 months post-randomization for patients given candesartan during adjuvant breast cancer treatment versus those who were not (1.7 vs 1.8 percentage points, P=0.91), reported Siri Heck, MD, PhD, of Akershus University Hospital in Lørenskog,…
-
General14 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News22 hours agoBetty’s Burgers National Burger Day
-
General14 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News23 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws